Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

被引：0

作者：

Wolchok, Jedd D.

Chiarion-Sileni, Vanna

Gonzalez, Rene

Rutkowski, Piotr

Grob, Jean Jacques

Cowey, Charles Lance

Lao, Christopher D.

Schadendorf, Dirk

Ferrucci, Pier Francesco

Smylie, Michael

Dummer, Reinhard

Hill, Andrew Graham

Haanen, John B. A. G.

Maio, Michele

McArthur, Grant A.

Yang, Arvin

Rollin, Linda

Horak, Christine E.

Larkin, James M. G.

Hodi, F. Stephen

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Oncol Inst Veneto IRCCS, Padua, Italy

[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

[5] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[6] Inst Oncol, Warsaw, Poland

[7] Hosp Timone, Marseille, France

[8] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[9] Univ Michigan, Ann Arbor, MI 48109 USA

[10] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany

[11] European Inst Oncol, Milan, Italy

[12] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[13] Univ Spital Zurich, Zurich, Switzerland

[14] Tasman Oncol Res, Southport, Qld, Australia

[15] Netherlands Canc Inst, Amsterdam, Netherlands

[16] Univ Hosp Siena, Siena, Italy

[17] Peter MacCallum Canc Ctr, East Melbourne, Australia

[18] Bristol Myers Squibb Co, Princeton, NJ USA

[19] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[20] Royal Marsden Hosp, London SW3 6JJ, England

[21] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1

引用

页数：1